

BTS Guideline for the investigation and management of pleural mesothelioma

Public consultation/Stakeholder comment form

Name: Prof Mark Strachan, Secreta	ary
Organisation: Royal College of Phy	sicians of Edinburgh
Please indicate if you are respondi	ng as an individual or on behalf of the organisation noted above:
Individual response:	
Organisation response:	X
Please add comments to the follow	ving table noting the section number and page number to which your

Note 'general' in the section column if your comments relate to the whole document.

comment refers.

Section	Page #	Comment
1304 1305	35	"Offer patients with MPM with good performance status first-line therapy with cisplatin, pemetrexed and bevacizumab. Grade A"
		Fellows expressed some concern over this statement, given the evidence of very limited improvement in survival over best supportive care over chemotherapy. There is no caveat over patient choice; the considerable toxicity of the regimes; and as to whether chemotherapy should be offered at all without considerable discussion.
		Fellows have related their own experiences, after reviewing many cases of mesothelioma, and often patients who have received chemotherapy will deteriorate, suffer considerable side-effects and fail to finish the chemotherapy. Patient choice must be considered, however Fellows queried the inclusion of the statement in its current form.
General	General	The College generally commends this very good attempt to clarify issues around the management of mesothelioma, in a field often lacking evidence.



Please add rows to this table as required.

Please return the completed form to:

Louise Preston

Project Manager: Education and Standards

British Thoracic Society 17 Doughty Street London WC1N 2PL Tel: 020 7831 8778 Fax: 020 7831 8766

louise.preston@brit-thoracic.org.uk

www.brit-thoracic.org.uk

Deadline: 5pm Monday 24th April 2017